Adarx Pharmaceuticals IPO Raises $446 M, Gains $15 M HBM Investment, Surges 30% on First Day
Adarx Pharmaceuticals’ IPO closed with $446 M raised, a $2.36 B valuation, and a $15.3 M follow‑on from HBM, fueling its siRNA drug pipeline and market credibility.
3 minutes to read